As previously reported, without anydoubt, anti-AD drug discovery is one of the main fields of applicationof the MTDLs design strategy.5 On the basisof the evidence pointing at GSK-3β as the functional link betweenAβ and tau and due to its involvement in multiple pathways controllingcrucial aspects of cell physiology, GSK-3β is gaining a lotof consideration as a drug discovery target. The gene discussed is MAPT; the disease is Alzheimer disease.